Potential mechanisms and challenges of combining anti-PD1 and antiCTLA-4

Describe and discuss the merits, potential mechanisms and challenges of combining anti-PD1 and antiCTLA-4 checkpoint blockade antibodies for the treatment of malignant melanoma.